[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Rhinovirus Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

October 2019 | 50 pages | ID: R23B5FB53D93EN
VPAResearch

US$ 1,699.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Rhinovirus Infections Drug pipeline report- 2020 is an annual R&D review of Rhinovirus Infections pipeline candidates. The report presents the current status of all major Rhinovirus Infections therapeutic compounds. Detailed insights into Rhinovirus Infections pipeline development, current status, companies, drug profiles and Rhinovirus Infections preclinical and clinical trials are included.

2020 Rhinovirus Infections Pipeline Market Insights
Rhinovirus Infections disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Rhinovirus Infections therapies, pipeline by phase and others are included.

Rhinovirus Infections pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Rhinovirus Infections Therapeutic Drug candidates
Both active and inactive Rhinovirus Infections pipeline drug candidates are included in the report

Rhinovirus Infections Clinical Trials and preclinical Studies
Rhinovirus Infections In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Rhinovirus Infections pipeline market developments
Rhinovirus Infections Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Rhinovirus Infections pipeline companies in active development
The report analyzes Rhinovirus Infections pipeline of the below companies-

ARMS Pharmaceutical LLC, AstraZeneca Plc, Biological Mimetics Inc, Enyo Pharma SA, Gilead Sciences Inc, Haplogen GmbH, Meissa Vaccines Inc, Polyrizon Ltd, PrEP Biopharm Ltd, Prokarium Ltd, Romark Laboratories LC, Sagimet Biosciences, Secarna Pharmaceuticals GmbH&Co.KG, Viravaxx AG

Report Coverage

What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies
14 Companies investing in Rhinovirus Infections pipeline from discovery stage to pre-registration phase are included

Drug profiles
Over 10 details of each Rhinovirus Infections pipeline candidate are included

Company Profiles
Business overview and contact details of all companies operating in the industry are provided

Market Developments
News, Developments and other recent industry developments are included
1. RHINOVIRUS INFECTIONS PIPELINE MARKET INSIGHTS, 2020

1.1 Rhinovirus Infections Disease Overview
1.2 Rhinovirus Infections Drug Pipeline Snapshot, 2020
  1.2.1 Rhinovirus Infections Pipeline Drugs by Phase
  1.2.2 Rhinovirus Infections Pipeline Drugs by Company
  1.2.3 Rhinovirus Infections Pipeline Drugs by Mechanism of Action
  1.2.4 Rhinovirus Infections Pipeline Drugs by Route of Administration

2. RHINOVIRUS INFECTIONS COMPANY WISE PIPELINE DETAILS

ARMS Pharmaceutical LLC Rhinovirus Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
AstraZeneca Plc Rhinovirus Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Biological Mimetics Inc Rhinovirus Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Enyo Pharma SA Rhinovirus Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Gilead Sciences Inc Rhinovirus Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Haplogen GmbH Rhinovirus Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Meissa Vaccines Inc Rhinovirus Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Polyrizon Ltd Rhinovirus Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
PrEP Biopharm Ltd Rhinovirus Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Prokarium Ltd Rhinovirus Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Romark Laboratories LC Rhinovirus Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Sagimet Biosciences Rhinovirus Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Secarna Pharmaceuticals GmbH&Co.KG Rhinovirus Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Viravaxx AG Rhinovirus Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details

3. RHINOVIRUS INFECTIONS DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. RHINOVIRUS INFECTIONS PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts


More Publications